7                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                  For the quarterly period ended June 30, 2005

                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

                                      09081

                                   CYBRDI INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

            CALIFORNIA                                     95-2461404
   -------------------------------                     -------------------
   (State or other jurisdiction of                      (I.R.S. Employer
    incorporation or organization)                     Identification No.)

       401 Rosemont Ave., Frederick, MD                        21701
     ---------------------------------------                ----------
     (Address of principal executive office)                (Zip Code)

Registrant's telephone number, including area code:    (301) 644-3901
                                                       --------------
                               Certron Corporation
      11845 W. Olympic Boulevard, Suite 1080, Los Angeles, California 90064
                           (Prior year end October 31)
      ---------------------------------------------------------------------
               Former name, former address and former fiscal year,
                         (if changed since last report)

Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [ ] No [x]

Indicate by a check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of
Common Stock as of the latest practicable date:

50,456,569shares of Common Stock, without par value, as of August 22, 2005

<PAGE>
                                      INDEX

                         PART I. - FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets as at June 30, 2005 (unaudited) and
December 31, 2004

Condensed Consolidated Statements of Income and Comprehensive Income (unaudited)
for three months ended June 30, 2005 and June 30, 2004; and for six months ended
June 30, 2005 and June 30, 2004.

Condensed Consolidated Statements of Cash Flow (unaudited) for six months ended
June 30, 2005 and June 30, 2004

Notes to Condensed Consolidated Financial Statements

Item 2. Management's Discussion and Analysis of Financial Condition and
        Results  of Operation

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Item 4. Controls and Procedures

                          PART II. - OTHER INFORMATION

Item 1. Legal Proceedings

Item 2. Unregistered Sales of Equity Securities

Item 3. Defaults upon senior securities

Item 4. Submission of matters to a vote of security holders

Item 5. Exhibits and reports on Form 8-K

                                       2
<PAGE>

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements


CYBRDI, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS AS OFJUNE 30, 2005 (UNAUDITED)
AND DECEMBER 31, 2004
================================================================================

<TABLE>
<CAPTION>
                                                                                   June 30,         Dec 31,
                                                                                     2005            2004
                                                                                 ------------    ------------
<S>                                                                             <C>              <C>
                                                                                  (unaudited)      (audited)
                                      ASSET
                                      -----
CURRENT ASSETS
Cash and cash equivalents                                                        $  3,623,435    $  3,899,706
Accounts receivable                                                                   574,827         252,179
Inventories                                                                           253,372         264,827
Other receivables and prepaid expenses                                                111,342           7,058
                                                                                 ------------    ------------
TOTAL CURRENT ASSETS                                                                4,562,976       4,423,770
PROPERTY, PLANT AND EQUIPMENT, NET                                                    565,611         628,897
INTANGIBLE ASSETS (NET)                                                               605,782         644,423
DEFERRED TAX ASSETS                                                                    40,171          40,171
                                                                                 ------------    ------------

TOTAL ASSETS                                                                     $  5,774,540    $  5,737,261
                                                                                 ============    ============

                      LIABILITIES AND STOCKHOLDERS' EQUITY
                      ------------------------------------
CURRENT LIABILITIES
Accounts payable                                                                 $     62,828    $         47
Other payables                                                                         56,674          59,133
Customer deposits                                                                       9,940              --
Dividends payable                                                                          --         138,507
Amount due to stockholders                                                            608,020         555,222
                                                                                 ------------    ------------
TOTAL CURRENT LIABILITITES                                                            737,462         752,909

MINORITY INTERESTS                                                                    943,871         884,691
                                                                                 ------------    ------------

TOTAL LIABILITIES                                                                   1,681,333       1,637,600
                                                                                 ------------    ------------

STOCKHOLDERS' EQUITY
Preferred Stock, $1.00 par value, 500,000 shares authorized,
zero shares issued and outstanding                                                         --              --
Common Stock, no par value in 2005 and $0.10 par value in 2004,
150,000,000 shares in 2005 and 30,210,000 shares in 2004 authorized,
50,456,569 shares in 2005 and 30,210,000 shares in 2004 issued and outstanding     50,456,569       3,021,000
Additional paid-in capital                                                        (47,063,505)        572,232
Reserve funds                                                                         240,416         240,416
Retained earnings                                                                     459,457         265,757
Accumulated other comprehensive income                                                    270             256
                                                                                 ------------    ------------
TOTAL STOCKHOLDERS' EQUITY                                                          4,093,207       4,099,661

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                       $  5,774,540    $  5,737,261
                                                                                 ============    ============
</TABLE>


                 The accompanying notes are an integral part of
               these condensed consolidated financial statements.

                                       3

<PAGE>

CYBRDI, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED)
FOR THREE AND SIX MONTHS ENDED JUNE 30, 2005 AND 2004
================================================================================

<TABLE>
<CAPTION>
                                               Three months     Three months    Six months      Six months
                                                   ended           ended          ended           ended
                                                  June 30,        June 30,       June 30,        June 30,
                                                   2005             2004           2005           2004
                                                ------------    ------------   ------------    ------------
<S>                                             <C>             <C>            <C>             <C>
Revenue
       Products                                 $    348,146    $    285,418   $    676,208    $    563,495
       Service rendered                               51,404          82,964         81,670         162,361
                                                ------------    ------------   ------------    ------------
          Total revenue                              399,550         368,382        757,878         725,856
                                                ------------    ------------   ------------    ------------
Cost of sales
       Products                                       58,732          67,558        107,874         112,966
       Service rendered                                5,176           9,071          8,652          17,825
                                                ------------    ------------   ------------    ------------
         Total cost of sales                          63,908          76,629        116,526         130,791
                                                ------------    ------------   ------------    ------------
Gross profit                                         335,642         291,753        641,352         595,065
                                                ------------    ------------   ------------    ------------

Operating expenses:
       Selling and distribution expenses              19,243          20,757         41,774          38,995
       General and administrative expenses           161,337         136,981        323,054         287,356
                                                ------------    ------------   ------------    ------------
Total operating expenses                             180,580         157,738        364,828         326,351
                                                ------------    ------------   ------------    ------------

Income from operations                               155,062         134,015        276,524         268,714
                                                ------------    ------------   ------------    ------------
Other income/(expense)
       Interest income                                   (62)          1,132          1,997           4,015
       Other (expense)/income, net                     1,894           4,082         (1,155)          4,661
                                                ------------    ------------   ------------    ------------
Total other (expense)/ income                          1,832           5,214            842           8,676
                                                ------------    ------------   ------------    ------------

Income before income taxes                           156,894         139,229        277,366         277,390
Income taxes                                          15,699              --         24,474              --
                                                ------------    ------------   ------------    ------------
Income before minority interest                      141,195         139,229        252,892         277,390
Minority Interest                                    (37,548)        (34,847)       (59,192)        (67,281)
                                                ------------    ------------   ------------    ------------

Net income                                           103,647         104,382        193,700         210,109
                                                ============    ============   ============    ============

Other comprehensive loss:
Foreign currency translation loss                         16              --            (14)             --
                                                ------------    ------------   ------------    ------------

Comprehensive income                            $    103,663    $    104,382   $    193,686    $    210,109
                                                ============    ============   ============    ============

Earnings per share, basic and diluted           $       0.00    $       0.00   $       0.00    $       0.00
                                                ============    ============   ============    ============

Weighted average number of shares outstanding     50,456,569      24,619,355     45,982,189      24,619,355
                                                ============    ============   ============    ============
</TABLE>


                 The accompanying notes are an integral part of
               these condensed consolidated financial statements.

                                       4

<PAGE>

CYBRDI INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
FOR THE SIX MONTHS ENDED JUNE 30, 2005 AND 2004
================================================================================

<TABLE>
<CAPTION>
                                                          Six months      Six months
                                                            ended           ended
                                                           June 30,        June 30,
                                                             2005            2004
                                                          -----------    -----------
<S>                                                       <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES
      Net income                                          $   193,700    $   210,109
      Adjustments to reconcile net income to net cash
        provided by operating activities:
      Depreciation and amortization                           101,927         97,817
      Minority interest's share of net income                  59,192         67,283
Changes in operating assets and liabilities:
      Accounts receivable, net                               (322,648)      (115,919)
      Inventories                                              11,454        (94,619)
      Other receivable and prepaid expenses                  (104,282)       293,435
      Accrued interest receivable                                  --          7,045
      Accounts payable and accrued expenses                    62,781         54,490
      Other payables and liabilities                           (2,457)          (487)
      Customer Deposit                                          9,940         (1,196)
                                                          -----------    -----------
      Net cash provided by operating activities                 9,607        517,958
                                                          -----------    -----------

CASH FLOWS FROM INVESTING ACTIVITIES
      Purchase of property, plant and equipment                    --         (8,651)
                                                          -----------    -----------
      Net cash (used in) investing activities                      --         (8,651)
                                                          -----------    -----------

CASH FLOWS FROM FINANCING ACTIVITIES
      Proceeds advanced from stockholders                      52,797         22,611
      Payment of dividend                                    (138,507)      (157,651)
      Payment for merger expenses                            (200,168)            --
      Payment for private placement costs                          --       (132,030)
                                                          -----------    -----------
      Net cash (used in) financing activities                (285,878)      (267,070)
                                                          -----------    -----------

NET (DECREASE) INCREASE IN CASH AND
      CASH EQUIVALENTS                                       (276,271)       242,237
      Effect of exchange rate changes on cash                      --             --
      Cash and cash equivalents, at beginning of period     3,899,706      2,065,586
                                                          -----------    -----------

CASH AND CASH EQUIVALENTS, AT END OF PERIOD               $ 3,623,435    $ 2,307,823
------------------------------------------=               ===========    ===========

SUPPLEMENTARY CASH FLOW INFORMATION
      Interest paid                                       $        --    $        --
                                                          ===========    ===========
</TABLE>


                 The accompanying notes are an integral part of
               these condensed consolidated financial statements.

                                       5

<PAGE>

CYBRDI, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Three Months and Six Months Ended June 30, 2005 (Unaudited)

NOTE A - BASIS OF PRESENTATION

Interim financial statements:

The accompanying financial statements and footnotes have been condensed and
therefore do not contain all disclosures required by generally accepted
accounting principles. The interim financial statements are unaudited; however,
in the opinion of Cybrdi Inc. (the "Company"), the interim financial statements
include all adjustments, consisting only of normal recurring adjustments,
necessary for a fair statement of the results for the interim periods. Results
for interim periods are not necessarily indicative of those to be expected for
the full year. It is suggested that these condensed consolidated financial
statements be read in conjunction with the December 31, 2004 audited
consolidated financial statements and the accompanying notes thereto.

Description of business and revenue recognition:

Until its acquisition of Cybrdi, Inc. on February 10, 2005, the Company's
business consisted primarily of the distribution of magnetic media products.
With the completion of the merger, all the magnetic media distribution business
activities have ceased and Certron's sole business is conducted through Cybrdi.
Cybrdi's focus is the field of biogenetics commercialization, specializing in
the rapid introduction of tissue microarray products and services in both the
international and Chinese markets.

Most of the Company's activities are conducted through its 80% equity ownership
in China Shaanxi Shaoying Bio-technology Co., Ltd. ("Chaoying Biotech") a
sino-foreign equity joint venture established in July 2000 in the People's
Republic of China. The Company, with its principal operations located in China,
aims to take advantage of China's abundant scientific talent, low wage rates,
less stringent biogenetic regulation, and the huge genetic population as it
introduces its growing list of tissue microarray products.

Revenue represents the invoiced value of goods sold recognized upon the delivery
of goods to customers and service income is recognized when services are
provided. Deferred revenue represents the undelivered portion of invoiced value
of goods sold to customers. Sales transactions not meeting all the conditions of
the full accrual method are accounted for using the deposit method of
accounting. Under the deposit method, all costs are capitalized as incurred, and
payments received from the buyer are recorded as customer deposits.

Reverse merger:

On February 10, 2005, (the "Closing Date") the Company closed on an Agreement
and Plan of Merger (the "Agreement") among Certron Corporation ("Certron"), a
California corporation, Certron Acquisition Corp., a Maryland corporation and a
wholly-owned subsidiary of Certron ("Acquisition Sub"), and Cybrdi, Inc., a
Maryland corporation ("Cybrdi - Maryland") relating to the acquisition by
Certron of all of the issued and outstanding capital stock of Cybrdi - Maryland
in exchange for shares of common stock of Certron that will aggregate
approximately 93.8% of the issued and outstanding common stock of Certron.
Pursuant to the terms of the Agreement, at the Closing Date (a) Acquisition Sub
has been merged with and into Cybrdi - Maryland, with Cybrdi - Maryland being
the surviving corporation, (b) the common stock of Cybrdi-Maryland has been
cancelled and converted into the right to receive shares of the common stock of
Certron at an exchange ratio of 1.566641609. This resulted in the issuance of
47,328,263 shares of the Certron's common stock , and (c) each share of the
common stock of Acquisition Sub has been converted in to and become one share of
the common stock of Cybrdi-Maryland. The share exchange has been accounted for
as a reverse merger under the purchase method of accounting. Accordingly, Cybrdi
Inc. will be treated as the continuing entity for accounting purposes and the
historical financial statements presented will be those of Cybrdi, Inc.

In connection with the Agreement, , on February 10, 2005, the Company amended
its articles of incorporation to authorize the issuance of 150 million shares of
common stock no par value and 500,000 shares of preferred stock, $1.00 par value
per share, none of which are issued or outstanding.

Concurrent with the filing of the Articles of Merger, all of the Company's then
existing officers and directors tendered their resignation and Yanbiao Bai was
appointed as our Chairman of the Board of Directors. Mr. Bai then nominated the
following individuals to serve on the Board of Directors: Larry Liu, James Pan,
Xue Bu, Lieping Chen and MinMin Qin. The new Directors subsequently elected Dr.
Lei Liu as Chief Executive Officer, Mr. Yanbiao Bai as President, and Mrs. Xue
Bu as Secretary and Treasurer.

On March 31, 2005 the Company's Board of Directors changed its fiscal year end
from October 31 to December 31. Certron's fiscal year end was changed to
correspond with the fiscal year end of Cybrdi - Maryland.

                                       6
<PAGE>

On April 2, 2005 the Company filed amendments to its articles of incorporation
to change its name from Certron Corporation to Cybrdi, Inc. The amendment was
approved by the required vote of shareholders in accordance with Section 902 and
Section 903 of the California Corporations Code.

Principles of consolidation:

The condensed consolidated financial statements include the accounts of Cybrdi,
Inc. and its wholly-owned subsidiaries and joint ventures.

All significant intercompany balances and transactions have been eliminated.

Recent Accounting Pronouncements:

In November 2004, the FASB issued SFAS No. 151, "Inventory Costs - an amendment
of ARB No. 43, Chapter 4." SFAS No. 151 clarifies the accounting that requires
abnormal amounts of idle facility expenses, freight, handling costs, and
spoilage costs to be recognized as current-period charges. It also requires that
allocation of fixed production overheads to the costs of conversion be based on
the normal capacity of the production facilities. SFAS No. 151 will be effective
for inventory costs incurred on or after July 1, 2005. The Company is currently
evaluating the impact of this standard on its consolidated financial statements.

On December 16, 2004, the Financial Accounting Standards Board ("FASB")
published Statement of Financial Accounting Standards No. 123 (Revised 2004),
Share-Based Payment ("SFAS 123R"). SFAS 123R requires that compensation cost
related to share-based payment transactions be recognized in the financial
statements. Share-based payment transactions within the scope of SFAS 123R
include stock options, restricted stock plans, performance-based awards, stock
appreciation rights, and employee share purchase plans. The provisions of SFAS
123R are effective for small business issuers as of the first interim period
that begins after December 15, 2005. Accordingly, the Company will implement the
revised standard in the fourth quarter of fiscal year 2005. Currently, the
Company accounts for its share-based payment transactions under the provisions
of APB 25, which does not necessarily require the recognition of compensation
cost in the financial statements (note 3(d)). Management is assessing the
implications of this revised standard, which may materially impact the Company's
results of operations in the fourth quarter of fiscal year 2005 and thereafter.


NOTE B - ASSETS

The June 30, 2005 balance sheet included total current assets of $4,562,976 and
non-current assets of $1,211,564. Of these amounts, approximately $3,623,435
cash is planned for funding current operations and for future business
expansion.

Other current assets also included inventories that are mainly finished goods
and very few raw materials. Inventories are stated at the lower of cost or
market. Cost of raw materials is determined on the basis of first in first out
method ("FIFO"). Finished goods are determined on the weighted average basis and
are comprised of direct materials, direct labor and an appropriate proportion of
overhead. Included in non-current assets are property, plant and equipment
mainly consisting of machinery used for product manufacturing located in the
People's Republic of China ("PRC"). Depreciation on property, plant and
equipment is computed using the straight -line method over the estimated useful
life of the assets. The majority of the assets have estimated useful lives of 10
years. Intangible assets include a patent. Effective January 1, 2002, with the
adoption of SFAS No. 142, intangible assets with a definite life are amortized
on a straight-line basis. The patent is being amortized over its estimated life
of 10 years.

NOTE C - LIABILITIES

The June 30, 2005 balance sheet included total liabilities of $1,681,333 of
which $943,871 represents the 20% minority interest in Chaoying Biotech.
Included in the total liabilities, $608,020 was due to stockholders who are also
officers of the Company. The amount is an advance to the Company to assist with
operations in prior years. This advance is non-interest bearing and has no set
repayment terms.

In accordance with the relevant tax laws and regulations of the PRC, Chaoying
Biotech is entitled to full exemption from Corporation Income Tax ("CIT") for
the first two years and a 50% reduction in CIT for the next three years,
commencing from the first profitable year after offsetting all tax losses
carried forward from the previous five years. As 2003 was Chaoying Biotech's
first profitable year, the Company begins to record 50% CIT provision for first
quarter of 2005. Effective tax rate is approximately 7.5% for the quarter and
six months ended June 30, 2005.

NOTE D - STOCKHOLDERS' EQUITY

As a result of the reverse merger (see Note A), the common stock of
Cybrdi-Maryland has been cancelled and converted into the right to receive
shares of the common stock of Certron at an exchange ratio of 1.566641609. This
resulted in the issuance of 47,328,263 shares of Certron's common stock. As of
June 30, 2005, the Company had 50,456,569 shares of common stock issued and
outstanding. Historical information of the surviving company is that of Cybrdi -
Maryland.

NOTE E - LEGAL PROCEEDINGS

There is no material pending legal proceedings to which the Company is a party.
The Company was notified by a letter dated June 2, 2000 received June 6, 2000
that the Company may have a potential liability from waste disposal in the
Casmalia Disposal Site at Santa Barbara County, California. The Company was
given a choice of either signing an agreement that would toll the statute of


                                       7
<PAGE>

limitations for eighteen (18) months in order to allow the Company to resolve
any liability with the government without incurring costs associated with being
named a defendant in a lawsuit, or becoming an immediate defendant in a lawsuit.
The Company signed the tolling agreement. On November 20, 2001, the tolling
agreement was extended for an additional 18 months. On May 20, 2003 the tolling
agreement was again extended for an additional 18 months and on November 24,
2004 the tolling agreement was again extended for additional 18 months. On June
29, 2004, the Company received a proposed settlement from the EPA in the amount
of $21,131. The Company is waiting for communication from the government
concerning payment of the proposed settlement. As of June 30, 2005, the Company
has accrued a sufficient amount to cover any potential liabilities from this
matter.

Item 2. Management's Discussion and Analysis of Financial Condition and
        Results of Operation

The following discussion and analysis should be read in conjunction with our
Financial Statements and Notes thereto appearing elsewhere in this Report on
Form 10-Q as well as our other SEC filings.

Plan of Operations

With the completion of the merger, management determined to discontinue
Certron's prior business operations, the sale of magnetic media distribution
tapes and products, and pursue business opportunities through Cybrdi, Inc. Most
of Cybrdi's activities are conducted through its 80% equity ownership in China
Shaanxi Shaoying Bio-technology Co., Ltd. ("Chaoying Biotech") a sino-foreign
equity joint venture established in July 2000 in the People's Republic of China.
Cybrdi became affiliated with Chaoying Biotech in March 2003. The Chaoying
Biotech joint venture agreement has a term of 15 years. The term of joint
venture may be extended upon the mutual consent of the parties.

The Company focuses on biogenetics commercialization. The business includes
sales of tissue microarray products and services. Tissue chips, also called
microtissue arrays, represent a newly developed technology providing
high-throughput molecular profiling and parallel analysis of biological and
molecular characteristics for hundreds of pathologically controlled tissue
specimens. Tissue arrays can provide rapid and cost-effective localization and
evaluation of proteins, RNA, or DNA molecules, which is particularly useful for
functioning genomic studies. Cybrdi manufactures both human and animal tissue
microarrays for a wide variety of scientific uses, including drug discovery and
development purposes.

Our principal operations are located in Shaanxi China, where we aim to take
advantage of China's abundant scientific talent, low wage rates, less stringent
biogenetic regulation, and the huge genetic population as it introduces its
growing list of tissue microarray products.

                                       8
<PAGE>

RESULTS OF OPERATIONS

THE FOLLOWING TABLE SETS FORTH CERTAIN ITEMS IN OUR UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF INCOME FOR THE THREE MONTHS ENDED JUNE 30, 2005 AND
JUNE 30, 2004; AND FOR THE SIX MONTHS ENDED JUNE 30, 2005 AND JUNE 30, 2004:


<TABLE>
<CAPTION>
                                              Three months    Three months    Six months      Six months
                                                 ended           ended          ended           ended
                                                June 30,        June 30,       June 30,        June 30,
                                                  2005            2004           2005            2004
                                                ---------       ---------      ---------       ---------
<S>                                          <C>          <C>         <C>          <C>         <C>
Revenue
       Products                                 $ 348,146       $ 285,418      $ 676,208       $ 563,495
       Service rendered                            51,404          82,964         81,670         162,361
                                                ---------       ---------      ---------       ---------
          Total revenue                           399,550         368,382        757,878         725,856
                                                ---------       ---------      ---------       ---------
Cost of sales
       Products                                    58,732          67,558        107,874         112,966
       Service rendered                             5,176           9,071          8,652          17,825
                                                ---------       ---------      ---------       ---------
         Total cost of sales                       63,908          76,629        116,526         130,791
                                                ---------       ---------      ---------       ---------
Gross profit                                      335,642         291,753        641,352         595,065
                                                ---------       ---------      ---------       ---------

Operating expenses:
       Selling and distribution expenses           19,243          20,757         41,774          38,995
       General and administrative expenses        161,337         136,981        323,054         287,356
                                                ---------       ---------      ---------       ---------
Total operating expenses                          180,580         157,738        364,828         326,351
                                                ---------       ---------      ---------       ---------

Income from operations                            155,062         134,015        276,524         268,714
                                                ---------       ---------      ---------       ---------
Other income/(expense)
       Interest income                                (62)          1,132          1,997           4,015
       Other (expense)/income, net                  1,894           4,082         (1,155)          4,661
                                                ---------       ---------      ---------       ---------
Total other (expense)/ income                       1,832           5,214            842           8,676
                                                ---------       ---------      ---------       ---------

Income before income taxes                        156,894         139,229        277,366         277,390
Income taxes                                       15,699              --         24,474              --
                                                ---------       ---------      ---------       ---------
Income before minority interest                   141,195         139,229        252,892         277,390
Minority Interest                                 (37,548)        (34,847)       (59,192)        (67,281)
                                                ---------       ---------      ---------       ---------

Net income                                        103,647         104,382        193,700         210,109
                                                =========       =========      =========       =========
</TABLE>


THREE MONTHS ENDED JUNE 30, 2005 COMPARED TO THREE MONTHS ENDED JUNE 30, 2004

Net Sales

Cybrdi generates two categories of revenues: tissue chip product and services.
The net sales increase to $399,550 for the three months ended June 30, 2005 from
$368,382 for the three months ended June 30, 2004.

Tissue Chip Product: sales increased along all product lines in the tissue chip
business. The net sales increased approximately $62,728 to $348,146 for the
three months ended June 30, 2005 as compared to $285,418 for the three months
ended June 30, 2004. The increase in net sales of our Tissue Chip business is
primarily attributable to the stronger sales in diabetes detection biological
chips.

Services: Fewer technical service orders were received during the second quarter
of 2005 as compared to 2004 resulting in a decrease in sales of $31,560;
declining to $51,404 from $82,964 for the three months ended June 30, 2005 as
compared to June 30, 2004. Gross Margin

Gross margin as a percent of sales was 84% and 79% for the three months ended
June 30, 2005 and 2004, respectively. Gross Profit for the three months ended
June 30, 2005 increased to $335,642 from $291,753 for the three months ended
June 30, 2004. Our gross margin increased as a result of increased operating
efficiencies and an increase in sales volume of higher gross margin biological
chips products.

                                       9
<PAGE>

Operating Expenses

Our operating expenses increased to $180,580 for the three months ended June 30,
2005 from $157,738 for the three months ended June 30, 2004. This is primarily
due to an increase in general and administrative expenses to $161,337 for the
three months ended June 30, 2004 from $136,981 for the three months ended June
30, 2004. This increase was mainly attributable to an increase in professional
fees and administrative expenses which Cybrdi incurred as a result of its
acquisition by Certron.

Income Taxes

The Company has not recorded a provision for federal income tax for quarter
ended June 30, 2005 due to utilization of net operating loss carry forward to
offset taxable income in United States. In accordance with the relevant tax laws
and regulations of the People's Republic of China, Chaoying Biotech is entitled
to full exemption from Corporation Income Tax ("CIT") for the first two years
and a 50% reduction in CIT for the next three years, commencing from the first
profitable year after offsetting all tax losses carried forward from the
previous five years. As 2003 was Chaoying Biotech's first profitable year, the
Company begins to record 50% CIT provision from the first quarter of 2005.
Effective tax rate is approximately 7.5% for the quarter ended June 30, 2005.

SIX MONTHS ENDED JUNE 30, 2005 COMPARED TO SIX MONTHS ENDED JUNE 30, 2004

Net Sales

Cybrdi generates two categories of revenues: tissue chip product and services.
Our net sales increase to $757,878 for the six months ended June 30, 2005 from
$725,856 for the six months ended June 30, 2004.

Tissue Chip Product: sales increased along all product lines in the tissue chip
business. The net sales increased approximately $112,713 to $676,208 for the six
months ended June 30, 2005 from $563,495 for the six months ended June 30, 2004.
The increase in net sales of our Tissue Chip business is primarily attributable
to the stronger sales in our diabetes detection biological chip.

Services: Fewer technical service orders were received during the first six
months of 2005 as compared to 2004 resulting in a decrease in sales of $80,691
to $81,670 for the six months ended June 30, 2005 from $162,361 for the six
months ended June 30, 2004.

Gross Margin

Gross margin as a percent of sales was 85% and 82% for the six months ended June
30, 2005 and 2004, respectively. Gross Profit for the six months ended June 30,
2005 increased to $641,352 from $595,065 for the six months ended June 30, 2004.
The gross margin increased as a result of operation efficiency and increase in
sales volume of higher gross margin biological chips products.

Operating Expenses

The operating expenses increased to $364,828 for the six months ended June 30,
2005 from $326,351 for the six months ended June 30, 2004. This is primarily due
to the increase in general & administrative expenses to $323,054 for the six
months ended June 30, 2005 from $287,356 for the six months ended June 30, 2004,
which was mainly attributable to an increase in professional fees and
administrative expenses as Cybrdi incurred additional professional fees during
the quarter ended March 31, 2005 as a result of Cybrdi , Maryland being acquired
by Certron. In addition, an increase in salespersons also contributed to the
increase in selling and distribution to $41,774 for the six months ended June
30, 2005 from $38,995 for the six months ended June 30, 2004.

LIQUIDITY AND CAPITAL RESOURCES

Operating working capital (accounts receivable plus inventory less accounts
payable) increased by $248,412 from $516,959 as of December 31, 2004 to $765,371
as of June 30, 2005. The increase was primarily due to an increase in accounts
receivable of $322,648 from $252,179 at December 31, 2004 to $574,827 at June
30, 2005, which was offset by a decrease in inventory of $11,455 from $264,827
at December 31, 2004 to $253,372 at June 30, 2005 and an increase in accounts
payable of $62,781 from $47 at December 31, 2004 to $62,828 at June 30, 2005.
Increase in net sales is attributable to the increase in account receivable and
decrease in inventory. A higher accounts receivable was due to late payment of
some major customers after June 30, 2005. Account payable increase is due to pay
off most vendors balance as of year end.

Cash provided by operating activities was $9,607 for the six months ended June
30, 2005 as compared to $517,918 provided for the six months ended June 30,
2004. The decrease in cash provided by operating activities for the six months
ended June 30, 2005 reflected reduction of net income, increased in accounts
receivable and increased prepayment for professional services.

                                       10
<PAGE>

There were no investing activities for the six months ended June 30, 2005 as
compared to capital spending of $8,651 for the six months ended June 30, 2004.
Financing activities for the six months ended June 30, 2005 consumed $285,877,
reflecting dividend payments of $138,507, payment of $200,168 in costs
associated with the reverse merger transaction and offset by a $52,798 advance
from shareholders.

With approximately $3.8 million of net working capital as of June 30, 2005, the
Company believes it will have sufficient resources to finance its operations for
the coming year.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this quarterly report on Form 10-Q contain or may contain
forward-looking statements that are subject to known and unknown risks,
uncertainties and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. These
forward-looking statements were based on various factors and were derived
utilizing numerous assumptions and other factors that could cause our actual
results to differ materially from those in the forward-looking statements. These
factors include, but are not limited to, economic, political and market
conditions and fluctuations, government and industry regulation, interest rate
risk, U.S. and global competition, and other factors. Most of these factors are
difficult to predict accurately and are generally beyond our control. You should
consider the areas of risk described in connection with any forward-looking
statements that may be made herein. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of
this report. Readers should carefully review this quarterly report in its
entirety, including but not limited to our financial statements and the notes
thereto. Except for our ongoing obligations to disclose material information
under the Federal securities laws, we undertake no obligation to release
publicly any revisions to any forward-looking statements, to report events or to
report the occurrence of unanticipated events. For any forward-looking
statements contained in any document, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995.

Critical Accounting Policies

Use of Estimates: The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ
materially from those estimates.

The preparation of financial statements in conformity with generally accepted
accounting principles (GAAP) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results may differ from those estimates.

Revenue recognition: Revenue represents the invoiced value of goods sold
recognized upon the delivery of goods to customers and service income is
recognized when services are provided. Deferred revenue represents the
undelivered portion of invoiced value of goods sold to customers. Sales
transactions not meeting all the conditions of the full accrual method are
accounted for using the deposit method of accounting. Under the deposit method,
all costs are capitalized as incurred, and payments received from the buyer are
recorded as customer deposits.

                                       11
<PAGE>

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign  Currency  Exchange  Risk

The majority of our net sales, costs and expenses are priced in Chinese
renminbi. Our assets are predominantly located inside China. Since 1994, the
exchange rate for Renminbi against the United States dollar has remained
relatively stable, with an exchange rate approximately RMB8.28 to US$1.00. On
July 21, 2005, China announced a revaluation of RMB and dropped its peg to the
US dollar. China is planning to move to a managed float against a basket of
currencies. The exchange rate has been adjusted to approximately RMB8.11 to
US$1.00, or an appreciation of 2%, and has remained relatively stable since
then. However, there can be no assurance that Renminbi will not be subject to
devaluation. We may not be able to hedge effectively against Renminbi
devaluation, so there can be no assurance that future movements in the exchange
rate of Renminbi and other currencies will not have an adverse effect on our
financial condition.

Item 4. Controls and Procedures.

An evaluation was carried out by the Company's chief executive officer and
treasurer of the effectiveness of the Company's disclosure controls and
procedures (as defined in Rule 13a-15e or 15(d)-15(e) of the Securities Exchange
Act of 1934) as of June 30, 2005. Based upon that evaluation, the chief
executive officer and the treasurer concluded that the design and operation of
these disclosure controls and procedures were effective after giving affect to
the acquisition of Cybrdi, Inc. by the Company and its obligations to comply
with applicable accounting and disclosure requirements.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

There is no material pending legal proceedings to which the Company is a party.
The Company was notified by a letter dated June 2, 2000 that the Company may
have a potential liability from waste disposal in the Casmalia Disposal Site at
Santa Barbara County, California. The Company was given a choice of either
signing an agreement that would toll the statute of limitations for eighteen
(18) months in order to allow the Company to resolve any liability with the
government without incurring costs associated with being named a defendant in a
lawsuit, or becoming an immediate defendant in a lawsuit. The Company signed the
tolling agreement. On November 20, 2001, the tolling agreement was extended for
an additional 18 months. On May 20, 2003 the tolling agreement was again
extended for an additional 18 months and on November 24, 2004 the tolling
agreement was again extended for additional 18 months. On June 29, 2004, the
Company received a proposed settlement from the EPA in the amount of $21,131.
The Company is waiting for communication from the government concerning payment
of the proposed settlement. As of June 30, 2005, the Company has accrued a
sufficient amount to cover any potential liabilities from this matter.

Item 2. Unregistered Sales of Equity Securities,

Pursuant to the Agreement and Plan of Merger (the "Agreement") among Certron
Corporation ("Certron"), a California corporation, Certron Acquisition Corp., a
Maryland corporation and a wholly owned subsidiary of Certron ("Acquisition
Sub"), and Cybrdi, Inc., a Maryland corporation ("Cybrdi - Maryland") relating
to the acquisition by Certron of all of the issued and outstanding capital stock
of Cybrdi - Maryland . We issued 47,328,263 shares of our common stock to the
shareholders of Cybrdi- Maryland. The transaction closed in February and the
shares were issued by the Company's transfer agent in June 2005. This
transaction was exempt from registration claimed under section 4(2) of the
Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated
hereunder. The transaction did not include a public distribution or offering.

Item 3. Defaults upon senior securities.

None.

                                       12
<PAGE>

Item 4. Submission of matters to a vote of security holders.

None.


Item 5. Exhibits and Report on Form 8-K

        (a) Exhibits:

            31.1   Rule 13(a)-14(a)/15(d)-14(a) Certification

            31.2   RULE 13A-14(A)/15D-14(A) CERTIFICATION

            32.1   Certification Under Section 906 of the Sarbanes-Oxley
                   Act of 2002

            32.2   Certification of Chief Executive Officer and Chief Financial
                   Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

        (b) Reports on Form 8-K:

            Form 8-K filed April 6, 2005

            Form 8-K filed April 29, 2005

            Form 8-K filed June 2, 2005

                                       13
<PAGE>

                                    SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                              CYBRDI, INC.


DATE:  August 22, 2005                        /s/ Larry Liu
                                              -----------------------
                                              Larry Liu
                                              Chief Executive Officer

                                       14